Psoriasis is caused by a combination of genetic, immunologic, and environmental factors. The vitamin D receptor (VDR) is involved in antiproliferative and prodifferentiation pathways in keratinocytes and exerts immunosuppressive effects. We aimed to investigate possible associations between VDR polymorphisms and psoriasis susceptibility and to evaluate functional effects of potential psoriasis-associated polymorphisms. We genotyped 108 patients with psoriasis and 268 healthy controls at 5 VDR polymorphisms (A-1012G, FokI, BsmI, ApaI, and TaqI) by TaqMan allelic-discrimination real-time polymerase chain reaction. We found a significant increased overall risk of psoriasis for the VDR A-1012G promoter polymorphism (odds ratio [OR]=2.43, 95% confidence interval [CI]: 1.15–5.13; p=0.05). A significant higher frequency (p=0.035) of the A allele was found in psoriatic cases compared with controls. In a case–case analysis, a statistically significant association between A-1012G and family history emerged (p=0.033). Furthermore, a significant association of A-1012G risk genotypes with a lower expression of VDR mRNA emerged (p=0.0028). Our data show that VDR promoter A-1012G polymorphism is associated with psoriasis risk and suggest that this polymorphism may modulate psoriasis risk by affecting VDR expression.
Get full access to this article
View all access options for this article.
References
1.
AcikbasI., SanlıB, TepeliE., ErginS., AktanS., and BagciH. (2012). Vitamin D receptor gene polymorphisms and haplotypes (Apa, I., Bsm, I., Fok, I., Taq I) in Turkish psoriasis patients. Med Sci Monit, 18, CR661–CR666.
2.
AlbanesiC., De PitàO, and GirolomoniG. (2007). Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes. Clin Dermatol, 25, 581–588.
3.
ArmstrongA.W., HarskampC.T., and ArmstrongE.J. (2012). The association between psoriasis and obesity: a systematic review and meta-analysis of observational studies. Nutr Diabetes, 2, e54.
4.
BoonstraA., BarratF.J., CrainC., HeathV.L., SavelkoulH.F., and O'GarraA. (2001). 1alpha,25-Dihydroxyvitamin d3 has a direct effect on naive CD4 (+) T cells to enhance the development of Th2 cells. J Immunol, 167, 4974–4980.
5.
BoymanO., ConradC., TonelG., GillietM., and NestleF.O. (2007). The pathogenic role of tissue-resident immune cells in psoriasis. Trends Immunol, 28, 51–57.
6.
ChenM.L., PerezA., SananD.K., HeinrichG., ChenT.C., and HolickM.F. (1996). Induction of vitamin D receptor mRNA expression in psoriatic plaques correlates with clinical response to 1,25-dihydroxyvitamin D3. J Invest Dermatol, 106, 637–641.
7.
ChomczynskiP., and SacchiN. (2006). The single-step method of RNA isolation by acid guanidinium thiocyanate–phenol–chloroform extraction: twenty-something years on. Nat Protoc, 1, 581–585.
8.
D'AlésioA., GarabédianM., SabatierJ.P., Guaydier-SouquièresG., MarcelliC., LemaçonA., Walrant-DebrayO., and JehanF. (2005). Two single-nucleotide polymorphisms in the human vitamin D receptor promoter change protein-DNA complex formation and are associated with height and vitamin D status in adolescent girls. Hum Mol Genet, 14, 3539–3548.
9.
Dayangac-ErdenD., KaradumanA., and Erdem-YurterH. (2007). Polymorphisms of vitamin D receptor gene in Turkish familial psoriasis patients. Arch Dermatol Res, 299, 487–491.
10.
DelucaH.F., and CantornaM.T. (2001). Vitamin D: its role and uses in immunology. FASEB J, 15, 2579–2585.
11.
FangY., van MeursJ.B., d'AlesioA., JhamaiM., ZhaoH., RivadeneiraF., HofmanA., van LeeuwenJ.P., JehanF., PolsH.A., and UitterlindenA.G. (2005). Promoter and 3′-untranslated-region haplotypes in the vitamin d receptor gene predispose to osteoporotic fracture: the rotterdam study. Am J Hum Genet, 77, 807–823.
12.
FeldmanD., ChenT., HirstM., ColstonK., KarasekM., and ConeC. (1980). Demonstration of 1,25-dihydroxyvitamin D3 receptors in human skin biopsies. J Clin Endocrinol Metab, 51, 1463–1465.
13.
GuillotX., SemeranoL., Saidenberg-Kermanac'hN., FalgaroneG., and BoissierM.C. (2010). Vitamin D and inflammation. Joint Bone Spine, 77, 552–557.
14.
HalsallJ.A., OsborneJ.E., EpsteinM.P., PringleJ.H., and HutchinsonP.E. (2009). The unfavorable effect of the A allele of the vitamin D receptor promoter polymorphism A-1012G has different mechanisms related to susceptibility and outcome of malignant melanoma. Dermatoendocrinol, 1, 54–57.
15.
HalsallJ.A., OsborneJ.E., PringleJ.H., and HutchinsonP.E. (2005). Vitamin D receptor gene polymorphisms, particularly the novel A-1012G promoter polymorphism, are associated with vitamin D3 responsiveness and non-familial susceptibility in psoriasis. Pharmacogenet Genomics, 15, 349–355.
16.
HeineG., HoeferN., FrankeA., NöthlingU., SchumannR.R., HamannL., and WormM. (2013). Association of vitamin D receptor gene polymorphisms with severe atopic dermatitis in adults. Br J Dermatol, 168, 855–858.
17.
HosomiJ., HosoiJ., AbeE., SudaT., and KurokiT. (1983). Regulation of terminal differentiation of cultured mouse epidermal cells by 1 alpha, 25 dihydroxyvitamin D3. Endocrinology, 113, 1950–1957.
18.
KayaT.I., ErdalM.E., TursenU., CamdevirenH., GunduzO., SoylemezF., and IkizogluG. (2002). Association between vitamin D receptor gene polymorphism and psoriasis among the Turkish population. Arch Dermatol Res, 294, 286–289.
19.
KragballeK., GjertsenB., DeHoopD., KarlsmarkT., vanDe KerkhofP., and LarkoO. (1991). Double-blind, right/left comparison of calcipotriol and betamethasone valerate in treatment of psoriasis vulgaris. Lancet, 337, 193–196.
20.
LeeY.H., ChoiS.J., JiJ.D., and SongG.G. (2012). Vitamin D receptor ApaI, TaqI, BsmI, and FokI polymorphisms and psoriasis susceptibility: a meta-analysis. Mol Biol Rep, 39, 6471–6478.
21.
LiuJ.L., ZhangS.Q., and ZengH.M. (2013). ApaI, BsmI, FokI and TaqI polymorphisms in the vitamin D receptor (VDR) gene and the risk of psoriasis: a meta-analysis. J Eur Acad Dermatol Venereol, 27, 739–746.
22.
LiuY., KruegerJ.G., and BowcockA.M. (2007). Psoriasis: genetic associations and immune system changes. Genes Immun, 8, 1–12.
23.
LowesM.A., BowcockA.M., and KruegerJ.G. (2007). Pathogenesis and therapy of psoriasis. Nature, 445, 866–873.
24.
MathieuC., and AdoriniL. (2002). The coming of age of 1,25-dihydroxyvitamin D(3) analogs as immunomodulatory agents. Trends Mol Med, 8, 174–179.
25.
MathieuC., van EttenE., DecallonneB., GuiliettiA., GysemansC., BouillonR., and OverberghL. (2004). Vitamin D and 1,25-dihydroxyvitamin D3 as modulators in the immune system. J Steroid Biochem Mol Biol, 89–90, 449–452.
26.
MildeP., HauserU., SimonT., MallG., ErnstV., HausslerMR, FroschP., and RauterbergE.W. (1991). Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J Invest Dermatol, 97, 230–239.
27.
MorrisonN.A., YeomanR., KellyP.J., and EismanJ.A. (1992). Contribution of trans-acting factor alleles to normal physiological variability: vitamin D receptor gene polymorphism and circulating osteocalcin. Proc Natl Acad Sci USA, 89, 6665–6669.
28.
NejentsevS., GodfreyL., SnookH., RanceH., NutlandS., WalkerN.M., LamA.C., GujaC., Ionescu-TirgovisteC., UndlienD.E., RønningenK.S., Tuomilehto-WolfE., TuomilehtoJ., NewportM.J., ClaytonD.G., and ToddJ.A. (2004). Comparative high-resolution analysis of linkage disequilibrium and tag single nucleotide polymorphisms between populations in the vitamin D receptor gene. Hum Mol Genet, 13, 1633–1639.
29.
OttiniL., SilvestriV., SaievaC., RizzoloP., ZannaI., FalchettiM., MasalaG., NavazioA.S., GrazianoV., BianchiS., ManoukianS., BarileM., PeterlongoP., D'AmicoC., VarescoL., TommasiS., RussoA., GianniniG., CortesiL., VielA., MontagnaM., RadiceP., and PalliD. (2013). Association of low-penetrance alleles with male breast cancer risk and clinicopathological characteristics: results from a multicenter study in Italy. Breast Cancer Res Treat, 138, 861–868.
30.
PoonA.H., GongL., Brasch-AndersenC., LitonjuaA.A., RabyB.A., HamidQ., LapriseC., WeissS.T., AltmanR.B., and KleinT.E. (2012). Very important pharmacogene summary for VDR. Pharmacogenet Genomics, 22, 758–763.
31.
PoonA.H., LapriseC., LemireM., MontpetitA., SinnettD., SchurrE., and HudsonT.J. (2004). Association of vitamin D receptor genetic variants with susceptibility to asthma and atopy. Am J Respir Crit Care Med, 170, 967–973.
32.
RucevićI, Barisić-DruskoV., Glavas-ObrovacL., and StefanićM. (2009). Vitamin D endocrine system and psoriasis vulgaris—review of the literature. Acta Dermatovenerol Croat, 17, 187–192.
33.
SaekiH., AsanoN., TsunemiY., TakekoshiT., KishimotoM., MitsuiH, TadaY., ToriiH., KomineM., AsahinaA., and TamakiK. (2002). Polymorphisms of vitamin D receptor gene in Japanese patients with psoriasis vulgaris. J Dermatol Sci, 30, 167–171.
34.
SaracenoR., MannheimerR., and ChimentiS. (2008). Regional distribution of psoriasis in Italy. J Eur Acad Dermatol Venereol, 22, 324–329.
35.
SmithE.L., WalworthN.C., and HolickM.F. (1986). Effect of 1,25-dihydroxyvitamin D3 on the morphological and biochemical differentiation of cultured human epidermal keratinocytes grown in serum-free conditions. J Invest Dermatol, 86, 709–714.
36.
SølvstenH., FoghK., SvendsenM., KristensenP., AströmA., KumarR., and KragballeK. (1996). Normal levels of the vitamin D receptor and its message in psoriatic skin. J Invest Dermatol Symp Proc, 1, 28–32.
37.
StefanicM., RucevicI., and Barisic-DruskoV. (2013). Meta-analysis of vitamin D receptor polymorphisms and psoriasis risk. Int J Dermatol, 52, 705–710.
38.
StumpfW.E., SarM., ReidF.A., TanakaY., and DeLucaH.F. (1979). Target cells for 1,25-dihydroxyvitamin D3 in intestinal tract, stomach, kidney, skin, pituitary, and parathyroid. Science, 206, 1188–1190.
39.
WangY., ZhuJ., and DeLucaH.F. (2012). Where is the vitamin D receptor?. Arch Biochem Biophys, 523, 123–133.
40.
WhitfieldG.K., RemusL.S., JurutkaP.W., ZitzerH., OzaA.K., Dang HT HausslerC.A., GalliganM.A., ThatcherM.L., Encinas DominguezC., and HausslerM.R. (2001). Functionally relevant polymorphisms in the human nuclear vitamin D receptor gene. Mol Cell Endocrinol, 177, 145–159.
41.
ZerwekhJ.E., YuX.P., BreslauN.A., ManolagasS., and PakC.Y. (1993). Vitamin D receptor quantitation in human blood mononuclear cells in health and disease. Mol Cell Endocrinol, 96, 1–6.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
